Home  About us  Contact
 

Plasma Adiponectin (plasma + adiponectin)

Distribution by Scientific Domains
Medical Sciences100%

Terms modified by Plasma Adiponectin

  • plasma adiponectin concentration
    		•
  • plasma adiponectin level
    		•

    Selected Abstracts

    Adiponectin Is a Link Among Inflammation, Insulin Resistance, and High-Density Lipoprotein Cholesterol But Is Not Associated With Paraoxonase Activity in Premenopausal Women

    JOURNAL OF CLINICAL HYPERTENSION, Issue 11 2009
    Pinar Cetinalp-Demircan PhD
    The aim of this study was to evaluate whether insulin sensitivity, inflammatory response, and plasma lipid profile are associated with circulating adiponectin levels in nondiabetic healthy women. The authors also assessed whether adiponectin has any effect on high-density lipoprotein cholesterol,linked paraoxonase 1 (PON-1) activity and on the susceptibility of low-density lipoproteins to oxidation. Plasma adiponectin was measured in 91 nondiabetic premenopausal women, and the patients were then divided into quartiles. Circulating adiponectin was found to be associated with body mass index (r=.55, P<.001). After adjustment for body mass index, adiponectin showed an inverse correlation with the homeostasis model assessment of insulin resistance (HOMA-IR) (r=,.41, P<.001) and a positive correlation with high-density lipoprotein cholesterol (r=.43, P<.001). In linear regression analysis, HOMA-IR, tumor necrosis factor ,, and high-density lipoprotein cholesterol levels were found to be independently associated with adiponectin. However, high-density lipoprotein cholesterol,linked PON-1 activity and the susceptibility of low-density lipoproteins to in vitro oxidation did not seem to be related to plasma adiponectin concentrations. [source]

    Pioglitazone in the treatment of NASH: the role of adiponectin

    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 6 2010
    A. Gastaldelli
    Summary Background, Plasma adiponectin is decreased in NASH patients and the mechanism(s) for histological improvement during thiazolidinedione treatment remain(s) poorly understood. Aim, To evaluate the relationship between changes in plasma adiponectin following pioglitazone treatment and metabolic/histological improvement. Methods, We measured in 47 NASH patients and 20 controls: (i) fasting glucose, insulin, FFA and adiponectin concentrations; (ii) hepatic fat content by magnetic resonance spectroscopy; and (iii) peripheral/hepatic insulin sensitivity (by double-tracer oral glucose tolerance test). Patients were then treated with pioglitazone (45 mg/day) or placebo and all measurements were repeated after 6 months. Results, Patients with NASH had decreased plasma adiponectin levels independent of the presence of obesity. Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01,0.001 vs. placebo). In the pioglitazone group, plasma adiponectin was significantly associated (r = 0.52, P = 0.0001) with hepatic insulin sensitivity and with the change in both variables (r = 0.44, P = 0.03). Increase in adiponectin concentration was related also to histological improvement, in particular, to hepatic steatosis (r = ,0.46, P = 0006) and necroinflammation (r = ,0.56, P < 0.0001) but importantly also to fibrosis (r = ,0.29, P = 0.03). Conclusions, Adiponectin exerts an important metabolic role at the level of the liver, and its increase during pioglitazone treatment is critical to reverse insulin resistance and improve liver histology in NASH patients. [source]

    Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome

    CLINICAL ENDOCRINOLOGY, Issue 6 2004
    Joachim Spranger
    Summary objective, The polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance predisposing to diabetes mellitus type 2 and atherosclerosis. Adiponectin is a recently discovered adipocytokine with insulin-sensitizing and putative antiatherosclerotic properties. The aim of the study was to elucidate determinants of circulating adiponectin levels and to investigate the potential role of adiponectin in insulin resistance in PCOS women. patients and measurements, Plasma adiponectin and parameters of obesity, insulin resistance and hyperandrogenism were measured In 62 women with PCOS and in 35 healthy female controls. results, Both in PCOS and controls, adiponectin levels were lower in overweight or obese women than in normal-weight women, without any difference between PCOS and controls after adjustment for body mass index (BMI). In PCOS and in controls there was a significant correlation of adiponectin with BMI (r = ,0·516, P < 0·001), fasting insulin (r = ,0·404, P < 0·001), homeostasis model sensitivity (HOMA %S) (r = ,0·424, P < 0·001) and testosterone (r = ,0·279, P < 0·01), but no correlation with androstenedione (r = ,0·112, P = 0·325), 17-OH-progesterone (r =,0·031, P = 0·784) or the LH/FSH ratio (r =,0·033, P = 0·753). Multiple linear regression analysis revealed that BMI and HOMA %S but not testosterone were independently associated with adiponectin plasma levels, explaining 16% (BMI) and 13% (HOMA %S) of the variability of adiponectin, respectively. In PCOS patients insulin sensitivity, as indicated by continuous infusion of glucose with model assessment (CIGMA %S) was significantly correlated with adiponectin (r = 0·55; P < 0·001), BMI (r =,0·575; P < 0·001), waist-to-hip ratio (WHR) (r =,0·48; P = 0·001), body fat mass assessed by dual-energy X-ray-absorptiometry (DEXA) [Dexa-fat (total) (r = ,0·61; P < 0·001) and Dexa-fat (trunk) (r = ,0·59; P < 0·001)] and with testosterone (r = ,0·42; P = 0·001). Multiple linear regression analysis demonstrated that markers of obesity such as BMI, total or truncal fat mass, age and adiponectin were independently associated with CIGMA %S, and that circulating adiponectin accounted for about 18% of the degree of insulin resistance in PCOS. By contrast, testosterone was not a significant factor, suggesting that PCOS per se did not affect insulin sensitivity independent from obesity, age and adiponectin. Metformin treatment for 6 months in insulin-resistant PCOS women (n = 9) had no effect on plasma adiponectin (P = 0·59) despite significant loss of weight and fat mass and improvement in hyperandrogenaemia. conclusions, PCOS per se is not associated with decreased levels of plasma adiponectin. However, circulating adiponectin is independently associated with the degree of insulin resistance in PCOS women and may contribute to the development and/or maintenance of insulin resistance independent from adiposity. [source]

    Plasma adiponectin in heart transplant recipients

    CLINICAL TRANSPLANTATION, Issue 1 2009
    Pierre Ambrosi
    Abstract:, Background:, The association between plasma adiponectin and metabolic syndrome may be impaired in heart transplant recipients, since renal failure is frequent among these patients. Thus, we studied the relationship between metabolic syndrome and plasma adiponectin in transplanted heart recipients. Methods:, Ninety-five heart transplant recipients were prospectively included 8.3 ± 5.6 yr after transplantation in this cross-sectional study. All patients had physical examination, echocardiography or routine biennial coronary angiography, and laboratory measurements. Results:, Metabolic syndrome was found in 31% of these patients. Plasma adiponectin was significantly lower in patients with metabolic syndrome (12.5 ± 8.3 ,g/mL) than in patients without (16.7 ± 9.4 ,g/mL, p = 0.03). Adiponectin levels were usually in the normal or high range (< 4 ,g/mL in only two patients). Low creatinine clearance was associated with higher plasma adiponectin (R=,0.26, p = 0.01). Plasma adiponectin was not significantly different between the 28 patients with angiographic evidence of graft vasculopathy (13.9 ± 9.5 ,g/mL) and the 67 patients without (16.1 ± 9.1 ,g/mL, p = 0.3). Conclusions:, Contrasting with a high frequency of metabolic syndrome in these patients, adiponectin levels were usually in the normal or high range, probably as a consequence of renal failure. This suggests that adiponectin is not a major determinant for insulin resistance among these patients. [source]

    Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients

    JOURNAL OF INTERNAL MEDICINE, Issue 5 2006
    M. CESARI
    Abstract. Objective., To investigate the association of plasma adiponectin levels with coronary artery disease (CAD), arterial hypertension (HT), and insulin resistance (IR) in nondiabetic Caucasian patients. Design., We measured plasma adiponectin levels, IR (HOMA index), and the CAD atherosclerotic burden (angiography-based modified Duke Index score) in 400 nondiabetic patients undergoing coronary angiography. HT was diagnosed by the European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines or if patients were on antihypertensive treatment. Results., Coronary artery disease was found in 62% of the patients and ruled out in the rest (non-CAD group). Plasma adiponectin levels were inversely related to the CAD score (, = ,0.12, P = 0.029) and predicted the coronary atherosclerotic burden independent of other cardiovascular risk factors. However, they were similar in NT and HT and showed no correlation with blood pressure values. In non-CAD, but not in CAD patients, they were lower in patients with than without IR (8.3 ± 1.2 vs. 11.3 ± 1.3, respectively; P = 0.007). Conclusions., In nondiabetic high-risk Caucasian patients plasma adiponectin levels are inversely related to CAD severity and IR; however, they are not strongly related to blood pressure values. [source]

    Pioglitazone in the treatment of NASH: the role of adiponectin

    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 6 2010
    A. Gastaldelli
    Summary Background, Plasma adiponectin is decreased in NASH patients and the mechanism(s) for histological improvement during thiazolidinedione treatment remain(s) poorly understood. Aim, To evaluate the relationship between changes in plasma adiponectin following pioglitazone treatment and metabolic/histological improvement. Methods, We measured in 47 NASH patients and 20 controls: (i) fasting glucose, insulin, FFA and adiponectin concentrations; (ii) hepatic fat content by magnetic resonance spectroscopy; and (iii) peripheral/hepatic insulin sensitivity (by double-tracer oral glucose tolerance test). Patients were then treated with pioglitazone (45 mg/day) or placebo and all measurements were repeated after 6 months. Results, Patients with NASH had decreased plasma adiponectin levels independent of the presence of obesity. Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01,0.001 vs. placebo). In the pioglitazone group, plasma adiponectin was significantly associated (r = 0.52, P = 0.0001) with hepatic insulin sensitivity and with the change in both variables (r = 0.44, P = 0.03). Increase in adiponectin concentration was related also to histological improvement, in particular, to hepatic steatosis (r = ,0.46, P = 0006) and necroinflammation (r = ,0.56, P < 0.0001) but importantly also to fibrosis (r = ,0.29, P = 0.03). Conclusions, Adiponectin exerts an important metabolic role at the level of the liver, and its increase during pioglitazone treatment is critical to reverse insulin resistance and improve liver histology in NASH patients. [source]

    Total and high molecular weight adiponectin concentrations in plasma of patients with end-stage renal disease before and after peritoneal dialysis

    NEPHROLOGY, Issue 3 2008
    JAE-HO PARK
    SUMMARY: Background: Adiponectin is an antiatherogenic adipocyte-derived proteins. The level of plasma adiponectin is inversely correlated to cardiovascular risk in patients with end-stage renal disease (ESRD). The aim of this study was to elucidate the changes of adiponectin concentrations in newly diagnosed ESRD patients after peritoneal dialysis. Methods: In 16 newly diagnosed ESRD patients, total concentrations of adiponectin and high molecular weight (HMW) adiponectin, the HMW ratio (HMWR; ratio of the plasma level of HMW adiponectin to that of total adiponectin), the body mass index (BMI), insulin concentrations, blood glucose and estimation of the insulin sensitivity index by the homeostasis model assessment (HOMRIR) were compared before and after 1 year of peritoneal dialysis. Results: Plasma total adiponectin was decreased from 15.52 ± 9.35 ,g/mL to 11.80 ± 6.84 ,g/mL (P = 0.046), HMW adiponectin was decreased from 9.05 ± 6.48 ,g/mL to 4.83 ± 4.15 ,g/mL (P = 0.009), and HMWR was decreased from 0.51 ± 0.18 to 0.35 ± 0.20 (P = 0.008). Total and HMW adiponectin/BMI ratio was decreased. The BMI was increased from 25.2 ± 5.7 to 25.8 ± 6.2 (P = 0.036). The HOMRIR, insulin level and lipid profile were not changed. Conclusion: Total adiponectin, HMW adiponectin and HMWR were decreased in newly diagnosed ESRD patients after 1 year of peritoneal dialysis. The factors that influence the decrease of the level of adiponectin should be studied in a larger prospective study. [source]

    Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man

    THE PROSTATE, Issue 15 2010
    Takamitsu Inoue
    Abstract BACKGROUND Plasma insulin concentration is increased in prostate cancer patients during androgen deprivation therapy (ADT) and hyperinsulinemia has been associated with aggressive prostate cancer behavior. To investigate the possible role of castration-induced hyperinsulinemia as a mechanism that may attenuate the beneficial effects of ADT in patients with prostate cancer, a murine model would be useful. We therefore investigated long-term metabolic effects of castration in several mouse models. METHODS We studied the long-term influence of castration on energy intake, body weight, glucose tolerance, plasma-insulin, plasma insulin-like growth factor-1 (IGF-1), plasma adiponectin, and plasma leptin in C57BL/6, Swiss nu/nu, and CB17 scid mice receiving various diets. In each case, mice were randomized to have either bilateral orchiectomy or a sham operation. RESULTS Energy intake, body weight, blood glucose levels in glucose tolerance test, plasma insulin, plasma IGF-1, and plasma leptin level in all had a trend to be decreased in castrated as compared to sham operated mice. Plasma adiponectin level was increased in the castrated mice. CONCLUSIONS The effects of castration on glucose, insulin, and related markers in several mouse models studied does not coincide with clinical observations; further studies in this area will require clinical research and/or the use of alternate models such as the dog. Prostate 70: 1628,1635, 2010. © 2010 Wiley-Liss, Inc. [source]

    Effect of individualized weight-loss programmes on adiponectin, leptin and resistin levels in obese adolescent boys

    ACTA PAEDIATRICA, Issue 9 2009
    M Elloumi
    Abstract Aim:, We investigate the effects of a 2-month weight-loss programme on plasma levels of adiponectin, leptin and resistin in obese adolescent boys. Methods:, Twenty-one obese adolescent boys (BMI = 30.8 ± 3.2 kg/m2) completed the weight-loss programme including: 1/ either energy restriction (R), 2/ or individualized exercise training at the point of maximum lipid oxidation (Lipoxmax) (E), 3/ or energy restriction and training (RE). Body composition, lipid oxidation and plasma levels of adiponectin, leptin and resistin were measured before and after intervention. Results:, Following the weight-loss programme, adolescents of the RE group showed an improvement of their body composition (p < 0.01), an increase in plasma adiponectin (+73.7%, p < 0.01) and a decrease in plasma leptin (,38.8%, p < 0.01) leading to an increase in adiponectine/leptin ratio (ALR, +144.4%, p < 0.01) higher than the R or E groups. E and RE groups only showed a similar significant increase in plasma resistin (p < 0.05) and a significant improvement of lipid oxidation rate at Lipoxmax (p < 0.01 and p < 0.001). In addition, in RE group, ALR is correlated with waist/hip and waist/height ratios, resistin level, homoeostasis mode assessment (HOMA-IR) index and Lipoxmax. Conclusion:, In obese adolescents boys, moderate exercise training completed at Lipoxmax and combined with energy restriction improves their ability to oxidize lipids, which is associated with a normalization of their adiponectin, leptin and resistin levels resulting in an improved insulin sensitivity, as attested by a higher ALR and a lower HOMA-IR. [source]

    Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome

    CLINICAL ENDOCRINOLOGY, Issue 6 2004
    Joachim Spranger
    Summary objective, The polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance predisposing to diabetes mellitus type 2 and atherosclerosis. Adiponectin is a recently discovered adipocytokine with insulin-sensitizing and putative antiatherosclerotic properties. The aim of the study was to elucidate determinants of circulating adiponectin levels and to investigate the potential role of adiponectin in insulin resistance in PCOS women. patients and measurements, Plasma adiponectin and parameters of obesity, insulin resistance and hyperandrogenism were measured In 62 women with PCOS and in 35 healthy female controls. results, Both in PCOS and controls, adiponectin levels were lower in overweight or obese women than in normal-weight women, without any difference between PCOS and controls after adjustment for body mass index (BMI). In PCOS and in controls there was a significant correlation of adiponectin with BMI (r = ,0·516, P < 0·001), fasting insulin (r = ,0·404, P < 0·001), homeostasis model sensitivity (HOMA %S) (r = ,0·424, P < 0·001) and testosterone (r = ,0·279, P < 0·01), but no correlation with androstenedione (r = ,0·112, P = 0·325), 17-OH-progesterone (r =,0·031, P = 0·784) or the LH/FSH ratio (r =,0·033, P = 0·753). Multiple linear regression analysis revealed that BMI and HOMA %S but not testosterone were independently associated with adiponectin plasma levels, explaining 16% (BMI) and 13% (HOMA %S) of the variability of adiponectin, respectively. In PCOS patients insulin sensitivity, as indicated by continuous infusion of glucose with model assessment (CIGMA %S) was significantly correlated with adiponectin (r = 0·55; P < 0·001), BMI (r =,0·575; P < 0·001), waist-to-hip ratio (WHR) (r =,0·48; P = 0·001), body fat mass assessed by dual-energy X-ray-absorptiometry (DEXA) [Dexa-fat (total) (r = ,0·61; P < 0·001) and Dexa-fat (trunk) (r = ,0·59; P < 0·001)] and with testosterone (r = ,0·42; P = 0·001). Multiple linear regression analysis demonstrated that markers of obesity such as BMI, total or truncal fat mass, age and adiponectin were independently associated with CIGMA %S, and that circulating adiponectin accounted for about 18% of the degree of insulin resistance in PCOS. By contrast, testosterone was not a significant factor, suggesting that PCOS per se did not affect insulin sensitivity independent from obesity, age and adiponectin. Metformin treatment for 6 months in insulin-resistant PCOS women (n = 9) had no effect on plasma adiponectin (P = 0·59) despite significant loss of weight and fat mass and improvement in hyperandrogenaemia. conclusions, PCOS per se is not associated with decreased levels of plasma adiponectin. However, circulating adiponectin is independently associated with the degree of insulin resistance in PCOS women and may contribute to the development and/or maintenance of insulin resistance independent from adiposity. [source]

    Cord plasma concentrations of adiponectin and leptin in healthy term neonates: positive correlation with birthweight and neonatal adiposity

    CLINICAL ENDOCRINOLOGY, Issue 1 2004
    Po-Jung Tsai
    Summary objective, Adiponectin is negatively associated with leptin, insulin and obesity in children and adults. Whereas increases in fetal insulin and leptin are associated with increased weight and adiposity at birth, the role of adiponectin in fetal growth has not yet been determined. The aims of this study were to examine the relationships between adiponectin and insulin, leptin, weight and adiposity at birth in healthy term infants. design and methods, Anthropometric parameters including weight, length, circumferences and skinfold thickness were measured, and plasma lipid profiles, insulin, leptin and adiponectin concentrations in cord blood samples from 226 singleton infants born at term after uncomplicated pregnancies were assayed. results, Cord plasma adiponectin, leptin and insulin levels correlated significantly and positively with birthweight (P = 0·001, P < 0·001, P < 0·001, respectively) and the sum of skinfold thicknesses (P < 0·001, P < 0·001, P < 0·001, respectively). Mean cord plasma adiponectin and leptin levels, but not insulin level, were significantly higher in large-for-gestational-age (LGA) infants compared with appropriate-for-gestational-age (AGA) infants. Cord plasma leptin concentration, but not adiponectin concentration, was significantly higher in female infants than in male infants (P = 0·003 and P = 0·94, respectively). Cord plasma adiponectin concentration correlated positively with leptin level (P = 0·007) but not with insulin level (P = 0·78). conclusions, High adiponectin levels are present in the cord blood. Cord plasma adiponectin and leptin levels are positively correlated with birthweight and adiposity. This suggests that adiponectin may be involved in regulating fetal growth. [source]

    Plasma adiponectin in heart transplant recipients

    CLINICAL TRANSPLANTATION, Issue 1 2009
    Pierre Ambrosi
    Abstract:, Background:, The association between plasma adiponectin and metabolic syndrome may be impaired in heart transplant recipients, since renal failure is frequent among these patients. Thus, we studied the relationship between metabolic syndrome and plasma adiponectin in transplanted heart recipients. Methods:, Ninety-five heart transplant recipients were prospectively included 8.3 ± 5.6 yr after transplantation in this cross-sectional study. All patients had physical examination, echocardiography or routine biennial coronary angiography, and laboratory measurements. Results:, Metabolic syndrome was found in 31% of these patients. Plasma adiponectin was significantly lower in patients with metabolic syndrome (12.5 ± 8.3 ,g/mL) than in patients without (16.7 ± 9.4 ,g/mL, p = 0.03). Adiponectin levels were usually in the normal or high range (< 4 ,g/mL in only two patients). Low creatinine clearance was associated with higher plasma adiponectin (R=,0.26, p = 0.01). Plasma adiponectin was not significantly different between the 28 patients with angiographic evidence of graft vasculopathy (13.9 ± 9.5 ,g/mL) and the 67 patients without (16.1 ± 9.1 ,g/mL, p = 0.3). Conclusions:, Contrasting with a high frequency of metabolic syndrome in these patients, adiponectin levels were usually in the normal or high range, probably as a consequence of renal failure. This suggests that adiponectin is not a major determinant for insulin resistance among these patients. [source]